Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences
Inés Llamas-Ramos completed her PhD at the age of 26 from The University of Salamanca, Salamanca, Spain. Currently, she is working as a physiotherapist in Salamanca. As well as her clinical work she is also fortunate to be able to work as a visiting professor at The University of Salamanca, in the Department of Nursing and Physiotherapy. She has published several articles about cancer and dry needling in reputed international journals and has been serving as an editorial board member of various medical journals.
The MSAS is a multidimensional tool developed to evaluate frequency, severity and distress of common symptoms present in cancer patients. The objective of this project is to show how to adapt and validate the Spanish version of the MSAS. MSAS scale was translated into Spanish and administered to 246 cancer patients aged between 18 and 85. They attended the Day Hospital to receive chemotherapy. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) and Rotterdam Symptom Checklist (RSCL) were used to test criterion validity. The results obtained were that TOTAL MSAS, physical symptom subscale (PHYS), psychological symptom subscale (PSYCH) and global distress index (GDI) reported high internal consistency: 0.891; 0.801; 0.825; 0.813 respectively. Exploratory factor analysis identified two factors structure and confirmatory factor analysis showed good adjustment rates. The emotional functioning subscale of EORTC QLQ-C30 highly correlated with PSYCH (r=-0.868; p<0.001) and GDI (r=-0.810; p<0.001) while social functioning subscale correlated with PSYCH (r=-0.704; p<0.001) and GDI (r=-0.624; p<0.001). The physical symptoms subscale of RSCL correlated with PHYS (r=0.876; p<0.001) and the psychological symptoms subscale with PSYCH (r=0.872; p<0.001). The conclusion of this study was that the Spanish version of MSAS was determined to be a valid and reliable scale in cancer patients.